Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma
Phase 2
Completed
- Conditions
- Follicular Lymphoma
- Registration Number
- JPRN-jRCT1080224541
- Lead Sponsor
- ovartis Pharma. K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A)
Radiographically measurable disease at screening
Exclusion Criteria
Evidence of histologic transformation
Follicular Lymphoma Grade 3B
Prior anti-CD19 therapy
Prior gene therapy
Prior adoptive T cell therapy
Prior allogeneic hematopoietic stem cell transplant
Active CNS involvement by malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method